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ABSTRACT
Objective The aim of this study was to provide a 
comprehensive evidence on risk factors for transmission, 
disease severity and COVID-19 related deaths in Africa.
Design A systematic review has been conducted to synthesise 
existing evidence on risk factors affecting COVID-19 outcomes 
across Africa.
Data sources Data were systematically searched from 
MEDLINE, Scopus, MedRxiv and BioRxiv.
Eligibility criteria Studies for review were included if they 
were published in English and reported at least one risk factor 
and/or one health outcome. We included all relevant literature 
published up until 11 August 2020.
Data extraction and synthesis We performed a systematic 
narrative synthesis to describe the available studies for each 
outcome. Data were extracted using a standardised Joanna 
Briggs Institute data extraction form.
Results Fifteen articles met the inclusion criteria of which 
four were exclusively on Africa and the remaining 11 papers 
had a global focus with some data from Africa. Higher rates 
of infection in Africa are associated with high population 
density, urbanisation, transport connectivity, high volume of 
tourism and international trade, and high level of economic 
and political openness. Limited or poor access to healthcare 
are also associated with higher COVID-19 infection rates. Older 
people and individuals with chronic conditions such as HIV, 
tuberculosis and anaemia experience severe forms COVID-19 
leading to hospitalisation and death. Similarly, high burden of 
chronic obstructive pulmonary disease, high prevalence of 
tobacco consumption and low levels of expenditure on health 
and low levels of global health security score contribute to 
COVID-19 related deaths.
Conclusions Demographic, institutional, ecological, health 
system and politico- economic factors influenced the spectrum 
of COVID-19 infection, severity and death. We recommend 
multidisciplinary and integrated approaches to mitigate the 
identified factors and strengthen effective prevention strategies.
INTRODUCTION
The COVID-19 is a recently emerged viral 
disease caused by a novel single- stranded 
enveloped RNA (RNA) virus, known as 
SARS- CoV-2.1 Since the first COVID-19 case 
was identified in Wuhan province in China, 
Strengths and limitations of this study
 ► Effective public health interventions against the 
COVID-19 pandemic require strong evidence on the 
risk factors associated with the disease.
 ► The present study is the first African- focused com-
prehensive systematic review of its kind on a wide 
range of risk factors associated with the entire spec-
trum of COVID-19 in the Africa region.
 ► Titles and abstracts of all publications identified by 
the search criteria were screened by two indepen-
dent reviewers of the team.
 ► Full- text articles were appraised using the Joanna 
Briggs Institute critical appraisal tools.
 ► The available data did not allow us to carry out 
meta- analysis nor firmly establish causal relation-
ships in the present study.
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in late December 2019, the virus has rapidly spread across 
the world and declared a global pandemic on 11 March 
2020.2 As of 10 January 2021, the number of confirmed 
COVID-19 cases in the world has reached over 89.44 
million with nearly 1.92 million deaths.3 Despite the late 
start of the pandemic, infection rate in Africa has been 
increasing exponentially with a total of 2.95 million 
confirmed cases and more than 70 thousand deaths as 
of 10 January 2021.4 The majority of reported cases in 
Africa were from South Africa and Egypt, while countries 
in Central Africa had recorded the least.
Given that the pandemic is caused by a novel strain 
of coronavirus with unknown original host,5 in the early 
stage of the outbreak, the risk factors associated with 
its transmission routes, severity and fatality risks were 
unclear. Several studies have been conducted to better 
understand the prognosis of the disease, though the level 
of uncertainty on viral shedding, transmissibility and 
disease severity remains high.6 Evidence indicates that the 
susceptibility to infection, being seriously ill and the risk 
of death are influenced by individual- level characteristics 
such as sociodemographic factors,7 behavioural traits8 
and pre- existing medical conditions.9
While the number of people affected by the virus in 
Africa remains to be the lowest by global standards, which 
in part may be linked to the youthful age structure of the 
population and partly to the limited capacity for large 
scale testing,10 it is anticipated that the pandemic may 
have a profound impact in the region. First and foremost, 
Africa’s health system is fragile. In addition, preventive 
strategies such as social distancing and hand washing, 
which have proved effective in reducing transmission 
in the rest of the world, are less likely to be practical in 
the region due to prevailing sociocultural and economic 
circumstances.11 Compared with other regions, Africa is 
home to a large number of people living in substandard 
housing, which are mostly dense, inadequately ventilated 
and have limited access to direct water supply. The way 
of life in the region is largely communal. People tend 
to attend weddings, religious and funeral services in 
Figure 1 PRISMA flow diagram. Figure 1 describes the flow diagram of the search strategy. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses.
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large numbers. Such societal and environmental factors 
along with the lack of awareness and access to preventive 
measures and the potential for low level of adherence 
(even when the resources are available) mean that the 
region will have the highest number of vulnerable popu-
lations for COVID-19 infection.12
Many countries have undertaken strict measures such 
as banning of public gatherings, complete lockdown of 
social and economic activities and closure of borders to 
prevent importation of cases.13 The number of new cases, 
however, continues to rise11 creating considerable pres-
sure on the healthcare system.14 In the absence of effec-
tive vaccine or therapy, the ability to effectively control 
the spread of the pandemic hence depends on effective 
monitoring of new cases and on better understanding of 
the factors related to modes of transmission and severity 
of the disease. A comprehensive systematic review of 
African- focused COVID-19 related studies is required to 
strengthen public health measures and response plan 
against the pandemic in the continent. This review aims 
to provide a comprehensive evidence on risk factors 
for transmission, disease severity and COVID-19 related 
deaths in Africa.
METHODS
Australia-based Ethiopian Researchers Network
At the beginning of April, 2020, a time when the COVID-19 
pandemic was spreading across the globe, a group of more 
than 50 Australian- based Ethiopian researchers, who are 
active academic faculties in Australian institutions along 
with Ethiopian PhD students, established a working group 
on ‘Ethiopia and the COVID-19 pandemic’ to examine 
various dimensions and consequences of COVID-19 in 
Ethiopia. Specifically, the working group focused on four 
distinct thematic areas: (1) on understanding the epide-
miology of COVID-19 in Ethiopia and around the globe 
and synthesising the lessons for the country, (2) assessing 
opportunities for reimagining the health system for 
COVID-19 pandemic response, (3) identifying potential 
pharmaceutical and non- pharmaceutical interventions 
and (4) measuring socioeconomic impact of COVID-19 in 
Ethiopia to support the Ethiopian government’s effort to 
mitigate the deadly impact of the pandemic on the popu-
lation. As part of the project under the first thematic area, 
we conducted a systematic review to synthesise the avail-
able evidence on COVID-19 in Africa on factors affecting 
infection rates, severity and related deaths.
Search strategy
This systematic review is reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses guidelines.15 Potentially eligible articles 
were systematically searched and retrieved from Medline, 
PubMed and Scopus up to 11 August 2020. The following 
search terms, tailored to each database were used: 
“COVID-19” OR “coronavirus disease” OR “SARS- COV-2” 
OR “2019 novel coronavirus” OR “2019- nCoV” AND 
“Africa”. The full search strategy is summarised in online 
supplemental appendix 1. We used Medical Subject 
Headings terms to identify synonyms and text words in 
the appropriate syntax of each database. The search was 
not limited by date of publication or study design. Refer-
ence lists of included studies were manually searched 
for additional relevant articles. Moreover, preprint arti-
cles from the MedRxiv and BioRxiv databases were also 
accessed to ensure wider coverage. However, search was 
restricted to studies conducted in Africa and the English 
language only.
Study selection criteria
The titles and abstracts of all publications identified 
by the search criteria were screened by two indepen-
dent reviewers of the team (AAA and BAD) to retrieve 
full texts for all relevant studies. Full- text articles were 
appraised using the Joanna Briggs Institute (JBI)16 
Table 2 Factors associated with COVID-19 infection, severity and related death in Africa
Outcome Theme Potential specific factors
Infection Demographic factors High number of people aged ≥65 years25 and high population density.21 25
Health system level factors Low number of physicians and hospitals22 and low BCG vaccination.24
Politico- economic factors High economic openness, strong political democracy,23 more imports of goods and 
services, wide international tourism, high international travel24 and city connectivity.20
Environmental factor Low mean temperature.23 25
Comorbid conditions Low malaria infection rate,9 25 28 high HIV infection rate and under-5 diarrhoeal disease.9
Severity Demographic factors High percentage of older age population profile.7 19
Comorbid conditions People with HIV, TB and anaemia.19 21
Death Health system policy factors Low prevention, detection, response and risk environment indices.27
Politico- economic factors More imports of goods and services, wide international tourism,24 low global health 
security index score27 and low health expenditure (percentage of GDP).26
Chronic illness and lifestyle 
factors
High prevalence of chronic illness and tobacco use.8
COPD, chronic obstructive pulmonary disease; GDP, gross domestic product; TB, tuberculosis.
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critical appraisal tools17 (online supplemental appendix 
2). All studies published in English and reported at 
least one risk factor and/or one health outcome were 
included in the review. We excluded letters to editors, 
correspondence, editorials and case studies. However, 
we included global studies that reported findings from 
any country in Africa.
Sociodemographic, lifestyle and behavioural, climate 
variables and chronic comorbid conditions, which can 
be at a community or national level, were considered as 
risk factors. Whereas COVID-19 infection rates, level of 
severity and COVID-19 related deaths were considered as 
outcomes. We adopted the definition of terms as reported 
in each of the included studies. Severity was referred for 
cases that required hospitalisation and are at high risk of 
death.
Data extraction
Seven members of the research team (HG, DNK, DMF, 
MW, ATG, BAD and AAA) extracted needed data using 
a standardised JBI data extraction form17 (online supple-
mental appendix 3). The extracted data included study 
authors, setting, population characteristics, study design, 
outcome and main findings on one or more risk factors 
and reported measure of association between risk factors 
and outcomes.
Quality and risk of bias assessment in individual studies
The JBI tools17 were used to assess the methodological 
quality and risk of bias (in design, conduct and analysis) 
of included studies (online supplemental appendix 2). 
The tool is used to assess the inclusion criteria, measure-
ment of exposure and outcome variables, confounding 
adjustment and appropriateness of statistical analysis. 
All authors who participated in the data extraction also 
assessed the quality of studies that they extracted.
Data synthesis
A systematic narrative synthesis was conducted to describe 
the available studies separately for each outcome. Four 
steps were applied in synthesising the data: (1) reading 
findings and results of each study systematically and 
comprehensively and assessing for relevance; (2) devel-
oping a preliminary synthesis through describing each 
included study, grouping findings by infection, severity 
and death and tabulate results to identify patterns; (3) 
organise factors linked to the outcomes described in step 
2 and thematise items around themes; and (4) explore 
the relationships of each factor within and among 
themes. Meta- analysis was not conducted because of 
the small number of studies identified for selected risk 
factors.
Patient and public involvement
Patients and/or the public were not involved in the 




The combined search terms identified 651 records 
(figure 1). After removing duplicates (n=52) and unre-
lated studies (n=584), 53 records were eligible for full- 
text screening. Finally, 15 studies7–9 18–29 met the inclusion 
criteria and were included in this systematic review. Table 1 
presents the main characteristics and outcomes of these 
studies. Four studies were exclusively on Africa.9 18 21 22 
Two studies7 29 assessed susceptibility to COVID-19 infec-
tion, nine studies7 9 18 20 22–25 28 evaluated COVID-19 infec-
tion, three studies7 19 21 examined severity of COVID-19 
infection and four studies8 24 26 27 assessed COVID-19 
related death. Four studies assessed more than one 
outcome.7 21 24 27 As described in table 1, most studies (13) 
were conducted among the general population. Study 
designs such as modelling (n=7), cross- sectional (n=2), 
genetics (n=1), survey (n=4) and spatio- temporal analysis 
(n=1) were used in the included studies. The number of 
participants of those included studies for review ranges 
from 446 to 1.7 billion participants—the studies with the 
largest sample size were modelling related studies. We 
have annexed the quality score of all included studies in 
online supplemental appendix 4.
Factors affecting COVID-19 infection, severity and related 
death
Demographic, institutional, economic, environmental, 
health system policy, lifestyle and political factors were 
reported to have an effect on prevention and spread of 
COVID-19, so were the presence and level of chronic 
conditions.7–9 18–29 For example, we found that COVID-19 
infection and related deaths were affected by political 
democracy and economic openness as measured by 
volume of imports of goods and services and international 
tourism. Furthermore, high rate of comorbid conditions 
was positively correlated with COVID-19 infection and 
related death, with people having one or more chronic 
conditions experiencing severe form of the disease. A 
detailed summary of all the relevant factors affecting the 
infection, severity and mortality related to COVID-19 is 
presented in table 2.
Quality and risk of bias assessment
Detailed results of the methodological quality and risk 
of bias assessment of individual studies according to the 
JBI tool are reported in online supplemental appendix 4. 
In summary, five (34%) studies scored 100%, six (40%) 
studies scored 80%–89% and three (20%) studies scored 
70%–79%. Excluding studies with low scores did not 
materially change the results.
DISCUSSION
The systematic review presents a comprehensive summary 
of the current evidence on risk factors of COVID-19 infec-
tion, severity and related deaths in Africa. Demographic, 
institutional, political and ecological factors were linked 
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with high COVID-19 infection rates in Africa. The study 
also revealed that severe forms of COVID-19 were asso-
ciated with comorbidities and specific demographic 
characteristics. Health system organisation and policy, 
politico- economic situation, prevalence of chronic condi-
tions and lifestyle factors increase the risk of deaths asso-
ciated with COVID-19.
African countries that heavily rely on international trade 
and tourism were likely to have higher infection rates than 
other countries in the region.23 24 As anticipated, the rate 
of COVID-19 infection was higher among densely popu-
lated countries given that the disease is mainly spread 
through close contact with infected persons.30 31 A similar 
finding was observed elsewhere.32
African countries enjoying a stable political democracy 
have an open economy and well- connected air and road 
network were found to have a higher risk of COVID-19 
infection.20 23 This could be attributed to the fact that 
countries with strong democracy have a laissez- faire 
administrative system, where people are not obliged to 
obey and practice some public health measures that may 
infringe freedom of movement and the pursuit of happi-
ness. Democratic systems also go hand in hand with law 
and order and a higher than average disposable income, 
which create opportunities for leisure and work- related 
travels both internally and internationally, which increase 
the risk of COVID-19 transmission. In addition, countries 
with open economies and high transport connectivity are 
characterised by high mobility, facilitating spread of the 
disease.
The studies included in this review reported mixed 
findings with regards to the effect of temperature on 
COVID-19 infection. For example, the current review 
indicated that people living in countries with warmer 
temperature are less likely to acquire infection.23 33 
Contrary to this observation, some African countries such 
as Egypt, which enjoys warm weather through the year, 
are highly affected by the virus as compared with other 
African countries with relatively cooler temperature.34 Yao 
and colleagues, however,35 demonstrated that tempera-
ture had no significant association with COVID-19 infec-
tion. As highlighted in the study,32 further investigation 
is required to determine the role of weather on transmis-
sion and spread of COVID-19.
Age, particularly being an older person, was associated 
with more severe forms of COVID-19 at admission to 
hospital.36 This might be explained by weaker immunity 
among older people. Patients with coinfections such as 
TB are more likely to experience severe forms of COVID-
19.21 TB infection is common in low- resource settings and 
among older adults with pre- existing conditions resulting 
in high vulnerability to severe form of COVID-19 infec-
tion.19 37 Evidence on the effect of COVID-19 on people 
with HIV and malaria is limited.38 A study by Karmen- 
Tuohy et al39 showed that being infected with HIV at 
the time of acquiring COVID-19 does not significantly 
increase the severity of illness or the risk of complications. 
However, further research is warranted as the available 
evidence is inconclusive. Most importantly, given the 
high burden of HIV and malaria in the Africa region, the 
molecular, genetic, clinical and environmental implica-
tions of COVID-19 on people living with HIV and malaria 
should be explored in greater detail.
Generally, patients with underlining chronic condi-
tions are at a higher risk of having sever COVID-19 and 
related mortality. For instance, a study conducted by Cox 
et al38 revealed greater risk and severe forms of COVID-19 
in patients with COPD. Findings of a meta- analysis of 
seven studies conducted in China also reported signifi-
cant association between COVID-19 and hypertension, 
chronic respiratory disease and cardiovascular disease.40 
These findings imply that countries with a high burden 
of chronic conditions are more likely to have more severe 
cases of COVID-19. People who died of COVID-19 had 
chronic hypertension, COPD and cardiovascular comor-
bidities than recovered patients.8 41 History of tobacco 
use was found to be associated with increased risk of 
COVID-19 death.8 42 Additionally, Zhou and colleagues43 
found that 50% of patients who died of COVID-19 had 
a history of secondary bacterial infections. Chen and 
colleagues44 also reported that bacterial and fungal coin-
fections increase the risk of COVID-19 related mortality. 
Thus, public health and medical services responding to 
the pandemic in Africa should be equipped with resources 
that enable the identification of cases with underlining 
chronic conditions and provide tailored interventions.
The present review revealed that countries with effec-
tive healthcare system such as a strong disease preven-
tion, case detection and response programme and have 
a strong global health security system in pace had lower 
case fatality rate.27 This was supported by a WHO report 
that the COVID-19 pandemic is straining health systems 
worldwide as health facilities have been overstretched 
and unable to operate effectively due to increased burden 
for health facilities and healthcare workers.45 Impor-
tantly, higher per capita expenditure on health signifi-
cantly reduces the risk of COVID-19 deaths.26 This could 
be attributed to the fact that a strong health system with 
sufficient resources is both adaptive, resilient and often 
has the required manpower and facilities to respond 
to the higher demand for medical staff and supplies in 
treating COVID-19 cases.
The study has the following limitations. First, the results 
reported in the paper with respect to associated factors 
do not necessarily imply causality as most of the included 
studies were based on either cross- country or cross- 
sectional designs that are not suitable for studying causal 
relationships. Second, we have used hospital admission 
as one of the indicators of severity, but this may not be 
a sufficient criterion given that in some countries, espe-
cially in the early stage of the pandemic, all symptomatic 
patients were systematically hospitalised to avoid trans-
mission. Third, included articles were limited to those 
written in English. Fourth, there is still limited evidence 
on COVID-19 in countries Africa (some of the included 
studies are even preprint and others are modelling based 
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studies), and the review was unable to provide a strati-
fied analysis by regions—authors of the modelling studies 
have already noted some limitations of the modelling 
studies. Future research on COVID-19 in the region and 
beyond should focus on robust epidemiological study 
designs that are suitable to capture causal relationships 
and long- term impacts of the disease.
CONCLUSIONS
This systematic review demonstrated that several demo-
graphic, institutional, political,economic, environmental, 
lifestyle and health system factors as well as comorbid 
conditions increased the risk infection, severe forms of 
COVID-19 and deaths related to the virus in the Africa 
region. The impacts of these factors should be factored in 
by African governments and their development partners 
while designing tailored and targeted interventions to 
mitigate effects of the disease in the region. Implementing 
complete lockdown measures for an extended period in 
African countries is difficult or at least not as easy as in 
western countries due to the region’s unique social and 
economic settings. Alternative and effective measures 
such as mandatory face mask use and strong contact 
tracing system could be the most feasible interventions to 
contain the pandemic in the region.46 However, it should 
be noted that even with a complete adherence to such 
public health measures, governments can only expect to 
mitigate the spread of the virus in the region. Eventually, 
safe and effective vaccines and drugs are required to end 
this pandemic.
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